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Protein tyrosine phosphorylation is a key regulatory process in virtually all aspects of cellular functions.  Dysregulation of protein 
tyrosine phosphorylation is a major cause of human diseases, such as cancers, diabetes, autoimmune disorders, and neurological 
diseases.  Indeed, protein tyrosine phosphorylation-mediated signaling events offer ample therapeutic targets, and drug discovery 
efforts to date have brought over two dozen kinase inhibitors to the clinic.  Accordingly, protein tyrosine phosphatases (PTPs) are 
considered next-generation drug targets.  For instance, PTP1B is a well-known targets of type 2 diabetes and obesity, and recent 
studies indicate that it is also a promising target for breast cancer.  SHP2 is a bona-fide oncoprotein, mutations of which cause juvenile 
myelomonocytic leukemia, acute myeloid leukemia, and solid tumors.  In addition, LYP is strongly associated with type 1 diabetes 
and many other autoimmune diseases.  This review summarizes recent findings on several highly recognized PTP family drug targets, 
including PTP1B, Src homology phosphotyrosyl phosphatase 2 (SHP2), lymphoid-specific tyrosine phosphatase (LYP), CD45, Fas 
associated phosphatase-1 (FAP-1), striatal enriched tyrosine phosphatases (STEP), mitogen-activated protein kinase/dual-specificity 
phosphatase 1 (MKP-1), phosphatases of regenerating liver-1 (PRL), low molecular weight PTPs (LMWPTP), and CDC25.  Given that 
there are over 100 family members, we hope this review will serve as a road map for innovative drug discovery targeting PTPs.
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Introduction
Target-based drug discovery has become the dominant strat-
egy in the pharmaceutical industry[1].  It focuses on a disease-
associated target with the goal of developing molecules 
modulating target activity to provide potential therapeutics 
for disease treatment.  In this process, target identification and 
validation play a pivotal role in the drug discovery project’s 
success.  The number of known drug targets is approximately 
300 for all approved therapeutic drugs, in which a large por-
tion of them belongs to ion channels, G protein coupled recep-
tors, and protein kinases[2].  Protein tyrosine kinases (PTKs) 
are a very important class of oncology drug targets with >20 
small molecule kinase inhibitors already FDA-approved 
for various cancer treatments, and a large number of kinase 
inhibitors are currently under various stages of clinic trials[3]. 
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PTKs and protein tyrosine phosphatases (PTPs) reversibly and 
coordinately control cellular protein tyrosine phosphorylation 
levels, which are important for nearly all cellular processes, 
such as growth, differentiation, migration, survival, and apop-
tosis[4].  
In Chinese philosophy, the concept of Yin-Yang is used to 
describe the importance of balance between two seemingly 
opposite or contrary forces in the natural world[5], and protein 
tyrosine phosphorylation and dephosphorylation represent 
exactly such a Yin-Yang relationship.  At the molecular level, 
the extent of tyrosine phosphorylation is precisely balanced by 
the actions of specific PTK(s) and PTP(s), which can either up- 
or downregulate downstream signaling pathways, depending 
on whether the phosphorylation activates or inhibits protein 
function[4].  Aberrant tyrosine phosphorylation resulting from 
the perturbed PTK-PTP balance can cause numerous human 
diseases.  Indeed, excessive tyrosine phosphorylation is a 
hallmark of cancer.  Given the great success of drug discovery 
targeting against PTKs and the fact that proper cellular tyro-
sine phosphorylation levels are controlled by the coordinated 
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activity of kinases and phosphatases, PTPs have been sug-
gested as next generation drug targets[6–8].  PTPs have been 
important topics of research in biomedical science for the past 
two decades, and a number of PTPs have been implicated in 
various human diseases, such as cancer, diabetes, autoim-
mune, and neurological diseases[9–11].  These findings have fur-
ther strengthened the belief that targeting PTPs could be the 
next frontier in drug discovery.
The PTPs constitute a large family of enzymes with 107 
members divided into 4 groups based on their protein 
sequences and functions (Figure 1)[8, 12].  The major group is 
class I PTPs, which includes 99 members, and each member 
shares a conserved active site sequence (H/V)C(X)5R(S/T) 
with the cysteine as the catalytic residue in the dephosphory-
lation reaction.  Class I is further divided into classic tyrosine-
specific PTPs, and tyrosine and serine/threonine dual-specific 
phosphatases (DUSP), with 38 and 61 members, respectively. 
Classical tyrosine-specific PTPs are composed of 17 cytosolic 
PTPs and 21 trans-membrane receptor-like PTPs, and the 
DUSPs are further divided into MKP, Myotubularin, CDC14, 
Slingshot, PTEN, PRL, and atypical DSP subclasses.  Class II 
PTP has only one member, the low molecular weight (LMW) 
PTP, and class III has three members, namely CDC25A, 
CDC25B, and CDC25C.  Class II and class III PTPs also have 
catalytic cysteine residues.  Class IV PTPs have 4 members 
with catalytic aspartic acid residues, which is in contrast to 
Class I, II, and III PTPs.  Class IV PTPs activities also require 
the presence of a metal ion, suggesting they have unique evo-
lution origins[13].
Given the large number of PTPs, a summary of potential 
drug targets is highly important and will serve as a road map 
for drug discovery efforts targeting PTPs.  Although reviews 
on similar topics are available[7, 14], they were published more 
than ten years ago, during which significant research advances 
have been made.  Thus, this perspective aims to provide 
an updated view on this subject and a summary of recent 
research findings.  We will cover well recognized and vali-
dated PTP targets in the field, including PTP1B, SHP2, LYP, 
CD45, FAP-1, STEP, MKP-1, PRL, LMWPTP, CDC25 (Figure 
2), with a focus on their implications in human diseases.
PTP1B in diabetes and cancer
PTP1B, encoded by the PTPN1 gene, is a ubiquitously 
expressed classical non-receptor PTP with 435 amino acids[15]. 
It has an N-terminal catalytic domain, two proline-rich 
sequences, and a C-terminal hydrophobic region (Figure 2). 
Biochemical and genetic studies have indicated that PTP1B 
is a key negative regulator of insulin and leptin signaling 
pathways (Figure 3A), which are important regulators of 
body weight, glucose homeostasis, and energy expenditure[16]. 
PTP1B downregulates insulin signaling by directly dephos-
phorylating insulin receptor (IR) and insulin receptor sub-
strates (IRS)[17, 18], while it regulates leptin signaling by dephos-
phorylating activated JAK2 and STAT3[19, 20].  PTP1B antibodies 
and small molecule inhibitors have been shown to increase 
insulin-stimulated IR, IRS and STAT3 phosphorylation[21, 22], 
suggesting that PTP1B inhibition could sensitize insulin and 
leptin signaling pathways.  Importantly, PTPN1-deficient mice 
exhibit enhanced insulin sensitivity and leptin hypersensitiv-
ity and have lower blood glucose and basal insulin levels. 
These mice were also more resistant to high-fat diet-induced 
weight gain[23, 24].  
Decreased insulin sensitivity is a hallmark of type 2 diabe-
tes, which accounts for 90% of diabetes cases.  In this regard, 
Figure 1.  Human PTP classification.  The gene encoding individual PTPs is shown in parenthesis after the PTP name.  PTPs discussed in this review are 
highlighted in italic and bold font.
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PTP1B has been considered a novel drug target for type 2 dia-
betes and obesity.  Many pharmaceutical companies, includ-
ing Abbott, Novo Nordisk, AstraZeneca, Eli Lilly, Merck, 
Novartis, Incyte, Wyeth, and ISIS, have shown strong interest 
in PTP1B[25, 26].  The combined efforts in developing PTP1B 
inhibitors have generated at least 4 drug candidates in clinical 
trials, including ertiprotafib, ISIS 113715, ISIS-PTP1BRx, and 
trodusquemine (Figure 4A)[26].  Notably, ISIS 113715 has been 
shown to improve glucose regulation and reduce LDL levels 
in type 2 diabetes patients in a phase 2 clinical trial.  The more 
potent candidate ISIS-PTP1BRx will replace ISIS 113715 for fur-
ther development, which aims to help patients whose disease 
is inadequately controlled by insulin and who are unrespon-
sive to existing oral drugs.  
Given its function in dephosphorylation of receptor tyro-
sine kinases, which are known to induce oncogenic signalling, 
PTP1B has also been regarded as a potential tumor suppressor. 
However, recent studies have revealed that PTP1B can pro-
mote tumorigenesis[27].  For example, PTP1B has been shown 
to activate c-Src in breast cancer cell lines by dephosphorylat-
ing its negative regulatory residue Y530[28] (Figure 3A).  PTP1B 
can also activate the Ras-Raf-ERK oncogenic signaling path-
way, most likely by dephosphorylating the scaffold protein 
p62Dok, which binds and activates p120RasGAP[29] (Figure 
3A).  Moreover, PTP1B overexpression has been recorded in 
72% of 29 human breast cancer samples examined, in compari-
son to healthy controls[30].  Its overexpression was detected in 
all stages of tumor development, and it correlated with ERBB2 
overexpression, a frequently amplified receptor tyrosine 
kinase in breast cancer.
To understand the interplay between PTP1B and ERBB2 
and to define PTP1B’s role in breast cancer tumorigenesis, 
mice expressing an activated ERBB2 gene were crossed with 
PTPN1-null mice[31, 32].  Compared to control mice, PTPN1-null 
mice had a significant delay in tumor onset and a decreased 
rate of lung metastasis.  Delayed tumor onset and decreased 
metastasis were also observed after treatment with a small 
molecule PTP1B inhibitor.  Although the mechanism under-
lying PTP1B deletion or inhibition in tumor development 
remains unclear, these data indicate that PTP1B is function-
ally linked to ERBB2 and plays a positive role in breast cancer 
tumorigenesis.  Recently, PTP1B overexpression was reported 
in colorectal cancer tissues, and its expression correlated with 
tumor differentiation, tumor invasion, lymph node metastasis, 
and TNM stage, which suggest that PTP1B may also play a 
positive role in colorectal cancer[33].  Therefore, PTP1B inhibi-
tion may be a novel strategy to treat these major human can-
cers.
SHP2 in cancer 
The Src homology-2 (SH2) domain-containing phosphatase 
2 (SHP2) encoded by the PTPN11 gene is a 593 amino acid 
classical non-receptor PTP.  It has two tandem N-terminal 
SH2 domains (N-SH2, C-SH2), a catalytic PTP domain, a 
C-terminal tail with two tyrosine phosphorylation sites (Y542 
and Y580) and a proline-rich region (Figure 2)[34, 35].  SHP2’s 
N-SH2 domain blocks access of SHP2’s substrates by bind-
ing to its active site pocket at resting state[36].  However, upon 
growth factor or cytokine stimulation, the N-SH2 domain 
preferentially binds to tyrosine-phosphorylated proteins, such 
as receptor tyrosine kinase or scaffold proteins, to open up 
the phosphatase active site for catalysis.  SHP2 is a positive 
regulator of the growth factor-mediated Ras-Raf-ERK path-
way, and its phosphatase activity is essential for Ras-Raf-ERK 
Figure 2.  The schematic PTP structure discussed in this review.  
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pathway activation[35].  Several presumptive mechanisms have 
been proposed for its positive effect on ERK activation (Fig-
ure 3B), as follows: SHP2 could dephosphorylate the RasGAP 
binding site on RTK and/or Gab1 to prolong Ras activation[37]; 
it could also dephosphorylate CSK binding sites on Paxillin 
to sequentially activate Src and Ras[38]; SHP2 may mediate the 
dephosphorylation of the negative Ras regulator Sprouty to 
activate the Ras-ERK signaling pathway[39, 40]; finally, SHP2 
could act as an adapter in Grb2/SOS complex recruitment, 
leading to Ras activation [41].  Moreover, SHP2 has been found 
to regulate PI3K-AKT, a well recognized oncogenic pathway, 
and SHP2 can regulate it in a ligand- and cell-dependent man-
ner[42, 43].  In addition, SHP2 has been indicated in JAK/STAT, 
JNK, and NF-κB signaling, which also have strong associations 
with various human cancers[44].
Clinical studies have shown that SHP2 mutations broadly 
exist in patients with Noonan Syndrome (NS), juvenile myelo-
monocytic leukemia (JMML), acute myelogenous leukemia 
(AML) and solid tumors[35, 44–46].  Not surprisingly, many muta-
tions lie between the N-SH2 and PTP domain, disrupting their 
intramolecular interactions[44] and leading to constitutive SHP2 
activation.  Specifically, SHP2 germ-line mutations are present 
in 50% of NS patients, and SHP2 somatic mutations are pres-
ent in 35% of sporadic JMML patients.  The high incidence of 
SHP2 mutations indicate that it is likely a causative gene in 
these two diseases.  Indeed, the SHP2 D61G mutation in mice 
phenocopies human NS, exhibiting characteristics such as 
smaller body size, serious cardiac defects, and reduced skull 
length[47].  Mice expressing JMML-linked SHP2 mutations 
(D61Y, D61G) exhibit myeloproliferative disorders similar to 
Figure 3.  The physiological/pathological signal pathways involving PTP1B (A), SHP2 (B), LYP and CD45 (C), FAP-1 (D), and STEP (E).  Arrow represents 
positive regulation.  T-bar represents dephosphorylation if it points to a phosphate group or specific pY, otherwise it represents negative regulation. 
Dashed lines in panel (D) represent binding interaction.  See the text for regulation details.
1231
www.chinaphar.com
He RJ et al
Acta Pharmacologica Sinica
npg
those observed in JMML patients, including myeloid expan-
sion, increased myeloid precursors, and granulocyte and mac-
rophage tissue infiltration[48].  Human JMML characteristics 
include myeloid colony growth without exogenous cytokine 
stimulation and bone marrow cell hypersensitivity to gran-
ulocyte-macrophage colony stimulating factor (GM-CSF)[49]. 
Expression of JMML mutations D61Y and E76K in mouse bone 
marrow-derived hematopoietic progenitor cells promotes cell 
cycle progression in the presence of low level GM-CSF and 
cell survival in minimal media conditions[50, 51], supporting a 
positive role for SHP2 in promoting JMML.  It was observed 
that pharmacological SHP2 inhibitors (eg, II-B08[52], crypto-
tanshinone[53], and #220-324[54] in Figure 4B) blocked the pro-
liferation of patient-derived bone marrow low density mono-
nuclear cells[52], mouse myeloid progenitor cells, and leukemic 
cells[53, 54] expressing the SHP2-activating mutation E76K.  In 
addition, SHP2 phosphatase activity is required for oncogenic 
KIT-induced myeloid cell growth and survival, and genetic 
deletion or pharmacological inhibition of SHP2 can inhibit 
myeloid cell growth.  SHP2 inhibitor alone or in combination 
with a PI3K inhibitor can prolong the survival of transplanted 
mice[55].  
A recent report has shown that SHP2 positively regulates 
HER2-positive and triple negative breast cancers, and SHP2 
knockdown in MCF10A human breast epithelial cells blocks 
HER2/3-induced tumor cell invasion in a 3-D cell culture 
model[56].  Treatment with SHP2 shRNAmiRs can eradicate 
tumor-initiating cells and block tumor growth and metasta-
sis in relevant xenograft mouse models[56].  Moreover, in the 
epidermal growth factor receptor (EGFR) inhibition-resistant 
lung cancer cell line H1975, SHP2 is required for EGF-stimu-
lated ERK1/2 phosphorylation and cell proliferation.  Addi-
tionally, SHP2 knockdown or inhibition is sufficient to reduce 
ERK1/2 activation and block cell growth.  This SHP2 inhibitor 
(II-B08) also has remarkable anti-tumor activity in xenograft 
mice[57].  Taken together, these data suggest that SHP2 is a bona 
fide proto-oncogene and that targeting SHP2 is a promising 
strategy for various cancer treatments, including AML, JMML, 
breast cancer, and lung cancer.
LYP in autoimmune disease
The PTPN22-encoded lymphoid-specific phosphatase (LYP) 
is a classical 807 amino acid non-receptor PTP[58].  It has an 
N-terminal catalytic domain and a C-terminal region with 4 
proline-rich motifs (P1-P4) (Figure 2).  LYP protein expres-
sion is restricted to hematopoietic tissues such as thymocytes 
and mature B cells and T cells.  LYP is a strong T cell receptor 
(TCR) signaling inhibitor, which mediates important immune 
Figure 4.  The structure of PTP1B (A), SHP2 (B), and LYP (C) inhibitors mentioned in this review.
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responses[59–61].  As shown in Figure 3C, LYP dephosphory-
lates tyrosine residues in the activation loop of the Src family 
kinases LCK (Y394) and FYN (Y420), and ZAP70 (Y493), which 
contributes to TCR signaling activation[62, 63].  LYP can also 
bind C-terminal Src kinase (CSK) through its proline rich P1 
region and CSK’s SH3 domain[64–66].  The LYP-CSK association 
might promote LYP’s function in inhibiting T cell activation, 
as CSK can phosphorylate negative regulatory tyrosine resi-
dues in LCK (Y505) and FYN (Y531)[62, 63].  LYP-null mice have 
elevated memory T cell activation and sustained TCR-induced 
phosphorylation of LCK (Y394) and ZAP70, although naive 
T cell functions remain normal[67].  These mice also spontane-
ously develop germinal centers with increased serum antibody 
levels.  These results are consistent with cellular studies and 
suggest that LYP negatively regulates T cell development and 
function.
Importantly, a single-nucleotide polymorphism (SNP) 
(C1858T) in the PTPN22 gene is associated with type 1 diabe-
tes (T1D) in many populations[60, 61, 68, 69].  Autoimmune diseases 
are caused by abnormal immune responses against normal 
organs or tissues.  In this case, T1D is the result of an autoim-
mune response of cytotoxic CD8 and CD4 positive T cells 
targeting insulin-producing β-cells.  The C1858T LYP SNP has 
also been linked to other autoimmune diseases, such as rheu-
matoid arthritis[70, 71], Graves disease[72, 73], myasthenia gravis[74], 
and systemic lupus erythematosus[75], suggesting that LYP is a 
general susceptibility gene in both systemic and organ-specific 
autoimmune diseases.  
The C1858T SNP in the PTPN22 gene encodes a mutant 
R620 LYP enzyme, which is 1.5 times more active than wild-
type enzyme[76].  The mutation falls within the P1 proline-rich 
region, which disrupts the interaction between the P1 region 
and the SH3 domain, severely impairing LYP-CSK complex 
formation[64–66, 76].  Interestingly, the R620W mutant more effec-
tively inhibits T cell signaling compared to wild-type LYP in 
human T cells and Jurkat T cells[76], which is contradictory to 
earlier notions that LYP cooperates with CSK to downregulate 
TCR signaling[62, 63].  However, recent studies demonstrated 
that LYP forms a complex with CSK in resting T cells; upon 
TCR stimulation, LYP dissociates from CSK, resulting in 
increased LYP partition to lipid rafts, where it dephosphory-
lates substrates such as LCK and ZAP70 to downregulate TCR 
signaling[77].  In contrast, the R620W mutant cannot bind CSK 
and is therefore recruited to lipid rafts in the resting state. 
This uncontrolled TCR downregulation produces a gain-of-
function phenotype and causes various human autoimmune 
diseases[77].  PTPN22 knock-in mice have been generated to 
express the analogous R619 W mutation[78, 79].  As the mice age, 
they exhibit effector T cell expansion and transitional, ger-
minal center, and B cell expansion, resulting in autoantibody 
development and systemic autoimmunity.  These mice dem-
onstrate the relevance of the LYP C1858T SNP in the increased 
risk of autoimmune diseases.  Moreover, LYP pharmacological 
inhibitors (eg, LVT-1[77], Comp 4[80], and Comp 8b[82] in Figure 
4C) are very effective in promoting T cell activation[77, 80] and 
enhancing LYP-mediated signaling in thymocytes and bone 
marrow-derived mast cells[81, 82].  In a passive systemic anaphy-
laxis mouse model, LYP inhibitors reduce calcium-mediated 
transcription and degranulation in mast cells and block ana-
phylaxis, highlighting the great therapeutic potential of LYP 
inhibitors in autoimmune disease treatment[82].
CD45 in autoimmune disease and cancer
CD45 was studied decades ago as a cell surface glyco-
protein[83, 84].  After the identification of mammalian PTP1B, 
sequence comparison indicated that CD45 has two tandem 
PTP domains in its cytosolic tail.  CD45 was then classified as 
a class I receptor-like PTP[85].  CD45 is encoded by PTPRC and 
has a molecular weight between 170 and 220 kDa with a highly 
glycosylated extracellular region, a single transmembrane 
domain, and two PTP domains D1 and D2 (Figure 2).  The D1 
PTP domain is catalytically active, but its activity requires the 
presence of the inactive D2 domain[86].  Many CD45 isoforms 
are generated by alternative splicing, and they primarily dif-
fer in their extracellular regions[87].  CD45 is expressed in the 
hematopoietic lineage such as T and B cells, and it is estimated 
to occupy up to 10% of total cell surface area, indicating its 
abundance in these cells[88].  
CD45 plays a critical role in T cell receptor and B cell recep-
tor signaling, and Src family kinase LCK and LYN are well-
characterized CD45 substrates in T cells and B cells, respec-
tively[89–91].  LCK’s kinase activity is required for TCR signal-
ing, and it phosphorylates the TCR complex and activates 
ZAP70 to initiate a T cell activation cascade (Figure 3C).  CD45 
dephosphorylates the LCK Y505 residue, which negatively 
regulates LCK activity when phosphorylated, to positively 
regulate T cell activation.  This is consistent with cellular stud-
ies in which CD45-deficient cells have increased levels of LCK 
Y505 phosphorylation[92–94].  CD45-null mice have T cell defects 
that can be rescued by an LCK Y505F mutant[95].  Interest-
ingly, LCK is hyperphosphorylated at site Y394 in CD45 defi-
cient cells[89, 96, 97], which is a positive regulatory residue and 
enhances LCK kinase activity when phosphorylated.  These 
data suggest that CD45 can also downregulate LCK activity. 
It has been suggested that Y505 phosphorylation affects T 
cell signaling at low CD45 levels, while its effect is counter-
balanced by Y394 phosphorylation at higher CD45 levels[98]. 
Similarly, CD45 regulates LYN in B cells where it dephosphor-
ylates the negative regulatory Y508 residue and the positive 
regulatory Y397 residue, thus controlling LYN kinase activ-
ity[99–101].  B cell development and B cell signaling responses are 
reduced in CD45-null mice upon ligation, including altered 
proportion of B cell subsets.  Other reported CD45 substrates 
include FYN and JAK in T cells[94, 102], HCK and LYN in macro-
phages[103], and LYN, HCK and FYN in dendritic cells[104].
Given its important role in immune signaling pathways, 
CD45 has been linked to many autoimmune diseases[105].  For 
example, a SNP in CD45’s exon 4 causes a C77G mutation 
and is associated with increased incidence of multiple scle-
rosis[106–108], HIV[109], autoimmune hepatitis[110], and systemic 
sclerosis[111].  The C77G mutation disrupts an exonic splicing 
silencer, which results in high molecular weight CD45 iso-
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form expression (eg, CD45RA, which has higher CD45 activ-
ity in cells due to decreased ability to form homodimers)[112]. 
Another SNP in exon 4 causes the C59A mutation and has also 
been reported to interfere with splicing in several multiple 
sclerosis multiplex family members, which results in CD45RA 
expression in memory T cells[113].  In contrast, a SNP in exon 6 
causes the A138G mutation and has a protective effect in hepa-
titis B infection and autoimmune Graves’ thyroiditis.  This SNP 
promotes exon skipping, which results in increased expression 
of the low molecular weight isoform CD45RO[114, 115].  In addi-
tion, the E613R mutation in mouse CD45 is thought to disrupt 
homodimer formation to cause aberrant CD45 activity, and its 
expression produces a phenotype characterized by lympho-
proliferative syndrome and autoimmune diseases[116].  These 
genetic studies indicate a dose-response curve between CD45 
and human autoimmune diseases, suggesting that CD45 is a 
good drug target for autoimmune disease treatment.
CD45 is broadly expressed and has been used in antibody-
mediated therapy against hematopoietic malignancies[117]. 
Earlier studies have demonstrated that a CD45 antibody 
killed CD45-positive leukemic cells via antibody-dependent 
and host-cell-mediated cytotoxicity.  However, a more gen-
eral strategy is CD45-based radioimmunotherapy in which 
the CD45 antibody is conjugated to a radioactive agent, such 
that a high dose of radiation is specifically delivered to hema-
topoietic tissue.  In a pilot study[118], 131I-coupled anti-CD45 
was assessed in 44 patients with high-risk acute leukemia or 
myelodysplasia for marrow transplantation.  Seven out of 
25 treated patients with acute myeloid leukemia/myelodys-
plastic syndrome survived disease-free for 15 to 89 months 
(median, 65 months) post-transplantation.  More recently, 
211At-coupled anti-CD45 treatment prior to hematopoietic stem 
cell transplantation improved the median survival of leuke-
mic mice in a dose-dependent fashion, and 211At-coupled anti-
CD45 faithfully localized to the marrow and spleen with mini-
mal toxicity[119].  In addition, leukemia mouse models treated 
with anti-CD45 antibody-streptavidin conjugate and subse-
quent administration of 213Bi- or 90Y-DOTA-biotin conjugate, 
survived leukemia-free for more than 100 days with minimal 
toxicity[120].  These data suggest that anti-CD45-based radioim-
munotherapy is a highly effective approach for hematopoietic 
malignancy treatment.
FAP-1 in cancer
PTPN13-encoded Fas-associated phosphatase 1 (FAP-1, also 
named PTP1E, PTP-BAS and PTPL1) is a 2485 amino acid clas-
sical non-receptor PTP[121–123].  It contains a KIND domain, a 
FERM domain, five PDZ domains, and a PTP catalytic domain 
(Figure 2).  The FERM domain binds to phosphatidylinosi-
tol 4,5-biphosphate, which targets FAP-1 to juxtamembrane 
regions[124], PDZ domains are responsible for protein-protein 
interactions[125], but the KIND domain has not been well-stud-
ied.  The structure of FAP-1’s catalytic domain is very similar 
to PTP1B in overall folding[126, 127].
One of the most important discoveries regarding FAP-1 is 
that it interacts with the cytosolic portion of the FAS recep-
tor[128], a tumor necrosis factor (TNF) receptor or death recep-
tor whose activation leads to cell apoptosis, and negatively 
regulates FAS-initiated apoptosis (Figure 3D).  Studies have 
shown that FAS receptor’s C-terminal tripeptide Serine-Leu-
cine-Valine (SLV) sequence is sufficient to bind FAP-1’s sec-
ond PDZ domain[129, 130], and by doing so, FAP-1 inhibits FAS 
receptor export to the cell surface[131].  FAP-1 can also bind the 
p75NTR intracellular domain, another TNF receptor family 
member, through the second PDZ domain, and negatively reg-
ulate p75NTR-mediated NF-κB suppression and pro-apoptotic 
signaling[132] (Figure 3D).  In addition, FAP-1 binds the very 
C-terminus of the tumor suppressor Adenomatous Polyposis 
Coli (APC) through its second PDZ domain, and APC is a 
β-catenin-associated scaffold[133].  Thus, FAP-1 may indirectly 
modulate β-catenin tyrosine phosphorylation and regulate cell 
adhesion, migration, and division (Figure 3D).  Other reported 
FAP-1 binding partners include IκBα, RhoGAP1, EphrinB1, 
and TRPM2[125].  IκBα is the only FAP-1 binding protein that is 
also dephosphorylated by FAP-1, suggesting that it is a puta-
tive FAP-1 substrate[134, 135].  IκBα tyrosine phosphorylation 
is a key element in NF-κB activation; therefore, FAP-1 may 
regulate NF-κB activation.  FAP-1 specifically dephosphory-
lates IRS-1 and blocks insulin-like growth factor-induced 
PI3K/AKT signaling pathway[136].  In addition, FAP-1 interacts 
with and dephosphorylates HER2 and inhibits growth factor-
induced HER2 signaling[137].  FAP-1-deficient mice are gener-
ally healthy but have increased T cell activity such as cytokine 
elaboration and improved host defense against K pneumonia 
lung infection, as evidenced by the 35-fold less living bacteria 
in their lungs compared to wild-type controls[138].  Independent 
knockout studies have shown that FAP-1-null mice develop 
normally but have a mild deficiency in motor neuron repair, 
and significantly reduced retinal glial numbers in cultures 
from lens-lesioned knockout mice compared to wild-type con-
trols[139, 140].
Because FAP-1 negatively regulates FAS-initiated cell apop-
tosis, it has been suggested to positively regulate tumorigen-
esis.  FAP-1 inhibits FAS-mediated apoptosis in pancreatic 
adenocarcinoma[141, 142] and melanoma[131], and FAP-1 and 
FAS expression highly correlate with cell survival in ovarian 
cancer[143], colon cancer[144], head/neck cancer[145], hepatocel-
lular carcinoma and hepatoblastoma [146, 147].  Ewing’s Sarcoma 
family of tumors (ESFT) is characterized by the formation of 
chimeric fusion protein EWS-FLI1, which is an oncogenic tran-
scriptional factor that promotes tumorigenesis[148].  FAP-1 has 
been identified as a EWS-FLI1 oncogenic fusion protein tran-
scriptional target[149].  FAP-1 is highly expressed in ESFT cells 
and patient tumor samples and is required for ESFT trans-
formed phenotype maintenance[150–152].  Reduction of FAP-1 in 
ESFT cells significantly reduces monolayer and soft-agar cell 
growth and increased sensitivity to etoposide-induced apop-
tosis[149].  
Studies have shown that FAP-1 expression is increased in 
SW480 colon carcinoma cells after treatment with the chemo-
therapeutic agent oxaliplatin.  siRNA knockdown of FAP-1 
reduces cell proliferation and promotes oxaliplatin-induced 
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cell apoptosis, suggesting that FAP-1 inhibition increases 
oxaliplatin efficacy in colon carcinoma treatment[153].  Tumor 
progression shares many characteristics with epithelial-to-
mesenchymal transition (EMT), and cells undergoing EMT are 
more resistant to apoptosis[154].  The miR-200 family of miR-
NAs is a fundamental marker and powerful regulator of EMT, 
as it maintains the epithelial phenotype by suppressing EMT-
inducing transcription factor ZEB1 and ZEB2 expression[155]. 
miR-200 family members are frequently downregulated during 
early malignant transformation but are subsequently upregu-
lated in advanced stages in several human cancers[156].  FAP-1 
has been identified as a miR-200c target, and it is responsible 
for the reduced sensitivity to FAS-mediated apoptosis in cells 
in miR-200-inhibited cells, providing a mechanism by which 
cancer cells with reduced miR-200 expression are less sensitive 
to FAS-mediated apoptosis[157] 
In contrast, there is also evidence that FAP-1 may be a tumor 
suppressor.  For example, reduced PTPN13 mRNA expres-
sion by promoter hypermethylation or allelic loss has been 
observed in gastric and hepatocellular carcinomas[158, 159], and 
FAP-1 knockdown enhances PLC5 cell proliferation[159].  In a 
large-scale mutational PTP analysis in colorectal cancers, 19 
PTPN13 mutations were identified, and 7 of them were in the 
PTP domain, which may impair FAP-1’s catalytic activity[160]. 
Nevertheless, with 8 domains, FAP-1 is among the largest 
intracellular PTPs, suggesting that it has multiple functions 
and may play positive or negative roles in a context-dependent 
manner.  Thus, FAP-1 is a promising chemotherapy target for 
irradiation-resistant cancer.
STEP in neurological diseases and disorders 
Striatal-enriched protein tyrosine phosphatase (STEP) is 
encoded by PTPN5 and is a classical and brain-specific PTP, 
with two alternative spliced isoforms (STEP46 and STEP61). 
STEP46 is cytoplasmic, while STEP61 localizes to the post-
synaptic density and endoplasmic reticulum[161–163].  STEP has 
a phosphatase domain similar to all other PTPs and a kinase 
interaction motif (KIM), which is also present in HePTP and 
PTP-SL (Figure 2).  The KIM domain allows STEP to interact 
with MAPKs, such as ERK and p38, and STEP dephosphory-
lates tyrosine residues in their activation loops to reduce ERK 
and p38 activation.  ERK activity is significantly higher in the 
striatum, CA2 region of the hippocampus, and central and lat-
eral nuclei of the amygdala in STEP-null mice.  Cultured neu-
rons from STEP-knockout mice have increased ERK phosphor-
ylation upon synaptic stimulation compared to neurons from 
wild-type controls[164].  The p38α·STEP complex structure has 
been solved by NMR and small-angle X-ray scattering data, 
providing a molecular basis of STEP recognition of p38α[165]. 
Notably, ERK is a very important player in synaptic and neu-
ronal plasticity and is an essential component in signaling 
pathways that regulate behavioral memory formation[166], and 
p38α has been implicated in the neurological disorder patho-
genesis[167, 168].  
STEP can mediate DHPG (dihydroxyphenylglycine)-induced 
AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor) internalization (Figure 3E), a central process in 
synaptic plasticity.  DHPG stimulation significantly increases 
STEP protein expression, which is likely responsible for GluR2 
(an AMPAR member) dephosphorylation and internalization. 
STEP-inactive mutants abolish AMPAR internalization[169]. 
In STEP knockout mice, GluR1 and GluR2 baseline synaptic 
expression is increased compared to wild-type littermates, and 
DHPG-stimulated GluR1 and GluR2 internalization is also 
abolished in these mice[169].  STEP can also regulate NMDAR 
(N-methyl-D-aspartate receptor) (Figure 3E), a glutamate 
receptor involved in synaptic plasticity and memory function. 
STEP blocks NMDAR exocytosis by dephosphorylating and 
inactivating Y420 of FYN kinase[170].  FYN positively regulates 
NMDAR exocytosis to neuronal surfaces by phosphorylating 
Y1472 in NR2B[171].  Alternatively, STEP can promote clathrin-
dependent NMDAR endocytosis by directly dephosphorylat-
ing Y1472 of NR2B[172, 173].
STEP has been linked to many neurological diseases and 
disorders, including Alzheimer’s disease (AD), Hunting-
ton’s disease (HD), schizophrenia, fragile X syndrome (FXS), 
hypoxic-ischemic brain injury, depression, and alcohol use 
disorders[174].  For example, STEP protein level and activity 
are upregulated in the prefrontal cortex of AD patients and in 
the cortex of an AD mouse model.  Interestingly, Aβ-enriched 
medium was sufficient to increase STEP expression and to 
decrease NR1 and NR2B surface expression in wild-type 
cultured cortical neurons and cortical slices, but not in STEP 
knockout cultures.  These data indicate that STEP is required 
for Aβ-induced NMDAR endocytosis[173, 175].  Schizophrenia is 
a mental disorder with behavioral and cognitive deficits par-
tially due to the disruption of glutamatergic signaling.  Schizo-
phrenia patients have significantly higher STEP expression in 
the postmortem anterior cingulated cortex and dorsolateral 
prefrontal cortex, and similar observations have been made 
in mice treated with the psychotomimetics MK-801 and phen-
cyclidine (PCP)[176].  In contrast, STEP knockout mice are less 
sensitive to acute and chronic PCP administration in terms of 
their locomotor and cognitive effects[176].  Furthermore, several 
typical and atypical antipsychotic medications for schizophre-
nia treatment can act through STEP, as antipsychotic treatment 
of mice induces protein kinase A-mediated STEP61 phosphory-
lation and inactivation and increased GluN1/GluN2B receptor 
surface expression[176].  
It has been suggested that STEP proteasome degradation is 
blocked in both AD and schizophrenia, leading to STEP accu-
mulation and glutamate receptor internalization, and further 
contributing to AD and schizophrenia pathogenesis[173, 176]. 
Alcohol is known to cause cognitive impairment and memory 
and learning disruption in alcohol abuse disorders, likely 
through hippocampal NMDAR inhibition.  Interestingly, STEP 
mediates alcohol’s inhibitory effects on neuronal NMDAR 
function.  This is further supported by STEP knockout stud-
ies in which alcohol-induced NMDAR function and fear-
conditioned responses were not observed.  However, STEP 
re-introduction into neuronal cultures and slices restored eth-
anol-induced biochemical and electrophysiological deficits[177]. 
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Taken together, STEP is a potential novel drug target for the 
treatment of AD, schizophrenia, alcoholism and addiction, 
among other neurological diseases and disorders.
MKP-1 in cancer and neurological disorders 
Mitogen-activated protein kinase phosphatases (MKPs) are a 
group of 11 dual-specificity protein phosphatases.  All MKP 
members are structurally similar with a PTP domain at the 
C-terminus, a KIM domain for MAPK recognition, and an 
N-terminal sequence for subcellular localization (Figure 2).  As 
their name implies, MKPs interact with and dephosphorylate 
pThr and pTyr in MAPK’s activation loop, including ERK, 
JNK, and p38, to downregulate MAPK activity[178].  MKP-1 
was the first identified family member with 367 amino acids, 
and it is an immediate early gene[179, 180].  It is ubiquitously 
expressed, but is expressed most highly in the heart, lungs 
and liver[179].  Its N-terminal LXXLL sequence allows exclusive 
MKP-1 nuclear localization[181].  MKP-1 preferentially dephos-
phorylates p38 and JNK and to a lesser extent, ERK (Figure 
5A)[180, 182–184].  Interestingly, MAPK activation can induce 
MKP-1 transcription upon growth factor stimulation or stress, 
creating a negative feedback regulation loop between MAPK 
and MKP-1[185].  In addition, MKP-1-null mice are viable, fertile 
and have no phenotypic or histologic abnormalities[186].  
MKP-1 is well studied in human cancers because of its direct 
association with MAPK, which is a key regulator of cell prolif-
eration, differentiation, survival, and apoptosis[187, 188].  MKP-1 
overexpression has been detected in many cancers, including 
colon, prostate, bladder, ovarian, breast, and NSCLC[189–194]. 
In prostate cancer, MKP-1 expression is inversely correlated 
with JNK activity and apoptotic marker expression[190, 192], and 
MKP-1 overexpression is associated with resistance to FAS-
induced apoptosis in the prostate cancer cell line DU145[195]. 
In breast cancer cells, MKP-1 overexpression protects against 
chemotherapy-induced apoptosis, including doxorubicin, 
mechlorethamine, and paclitaxel.  In contrast, siRNA knock-
down of MKP-1 sensitizes cells to chemotherapy-initiated 
apoptosis by increasing JNK activity[196].  Proteasome inhibi-
tion induces MKP-1 expression by decreasing JNK activity. 
MKP-1 knockdown also increases cell sensitivity to protea-
some inhibitors[197].  In a clinical study with 96 patients, MKP-1 
overexpression correlates with likelihood of relapse compared 
to patients with normal MKP-1 levels[198].  In addition, MKP-1 
is strongly expressed in NSCLC tumor tissues and the H-460 
and H-23 cell lines.  siRNA knockdown of MKP-1 resulted in a 
ten-fold increase in cisplatin sensitivity[199].  Moreover, tumors 
induced by MKP-1 siRNA H-460 grow slower in xenograft 
mouse models and show increased cisplatin susceptibility 
compared to parental cell control tumors[199].  These results 
suggest that MKP-1 is an important cancer target that may 
increase the effects of chemotherapy.
MAPK is associated with memory and learning, neuronal 
plasticity and development[200].  As a MAPK regulator, MKP-1 
may thus play important roles in many brain functions.  MKP1 
is a transcriptional c-Jun target, and MKP-1 antagonizes JNK-
dependent apoptosis in sympathetic neurons[201].  MKP-1 
overexpression blocks JNK-mediated c-Jun phosphorylation 
and subsequent sympathetic neuron apoptosis, while MKP-1 
knockdown enhances nerve growth factor (NGF) withdrawal-
induced death.  Loss of MKP-1 results in decreased numbers 
of superior cervical ganglion neurons at P1 during develop-
mental sympathetic neuron death[201].  These results suggest 
that MKP-1 is part of a negative feedback loop to modulate 
MLK-JNK-c-Jun signaling.  Neurotrophin brain-derived neu-
rotrophic factor (BDNF) can induce MKP-1 expression to regu-
late outgrowth and activity-dependent remodeling of axonal 
arbors in vivo, which causes spatiotemporal JNK dephos-
phorylation and its substrates and contribute to microtubule 
destabilization[202].  Neurons from MKP-1 knockout mice can-
not produce BDNF-induced axon branches.  Because axonal 
arbor formation and maturation is strongly associated with 
increased synaptic connectivity and are positively regulated 
by BDNF, MKP-1 may play an important role in synaptogen-
esis.  Furthermore, MKP-1 dysregulation may have deleterious 
effects on learning and memory, which depend on plastic-
ity[203].  
MKP-1 is also a key factor in major depressive disorder 
(MDD) pathophysiology[204].  In rat and mouse models, hip-
pocampal MKP-1 expression increases upon stress or viral-
mediated gene transfer, leading to depressive behaviors. 
Chronic treatment with antidepressants normalizes stress-
induced MKP-1 expression and depressive behaviors[204].  It 
was observed that MKP-1 knockout mice are more resistant 
to stress compared to wild-type littermates, and this effect 
is mediated by increased ERK activity, consistent with stud-
ies that MEK-ERK signaling is essential for antidepressant 
responses[204].  Moreover, MKP-1 expression is significantly 
Figure 5.  The physiological/pathological signal pathways involving 
MKP-1 (A) and PRL1/2/3 (B).  Arrow represents positive regulation.  T-bar 
represents dephosphorylation if it points to a phosphate group or specific 
pY, otherwise it represents negative regulation.  See the text for regulation 
details.
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increased in postmortem hippocampal tissues from 21 indi-
viduals with depression compared to samples from 18 healthy 
age, gender, tissue pH and postmortem interval-matched con-
trols, indicating a direct clinical association between MKP-1 
overexpression and depression[204].  Thus, MKP-1 may also be 
a novel and promising drug target for the treatment of depres-
sion and other mood disorders.
PRLs in cancer
PRLs (phosphates of regenerating liver) are a subclass of 
dual specific phosphatases with 3 similar members, PRL1, 
PRL2 and PRL3[205].  PRLs have an N-terminal PTP catalytic 
domain, a C-terminal polybasic region, and a prenylation 
CAAX sequence (Figure 2), which is a unique feature to this 
subclass and is responsible for PRL plasma or intracellular 
membrane localization[206, 207].  Given their similarities, PRLs 
act redundantly in many biological functions (Figure 5B).  For 
example, both PRL1 and PRL3 regulate focal adhesion contact 
though Src activation, although PRL1 does so by enhancing 
Y419 phosphorylation in the kinase activation loop[208], while 
PRL3 downregulates the negative Src regulator CSK, leading 
to a decrease in Y530 autoinhibitory Src phosphorylation[209]. 
PRL2 targets p130CAS signaling to regulate Src-independent 
focal adhesion contact[210].  PRL1 and PRL3 can downregulate 
the p53 tumor suppressor by stabilizing MDM2 and increas-
ing PIRH2 transcription[211, 212], whereas PRL2 regulation of p53 
has not been elucidated.  In addition, PRL1 and PRL3 can both 
activate and promote matrix metalloproteinase (MMP) expres-
sion, extracellular secreted proteins with important roles 
in tumor metastasis.  PRL1 upregulates MMP2 and MMP9 
through Src and ERK activation[213], whereas PRL3 upregulates 
MMP2 and MMP7, but not MMP9, via integrin β1 and ERK 
pathways[214].
Given their role in regulating p53 and MMPs, PRLs 
may play important roles in human cancer pathophysi-
ology[205, 215, 216].  For example, PRL1 is overexpressed in lung 
and pancreatic cancer cell lines with increased invasive prop-
erties, which are reversed by PRL1 knockdown[208, 213, 217, 218]. 
PRL2 is overexpressed in pancreatic, breast and lung cancer, 
as well as pediatric AML.  PRL2 expression levels are associ-
ated with tumor progression and poor prognosis[210, 217, 219, 220]. 
In addition, PRL3 overexpression is widely found in cancers, 
including colon, breast, gastric, oral, cervix, and ovarian carci-
nomas, multiple myelomas and AML[215, 221].  In colon cancer, 
PRL3 overexpression positively correlates to poor progno-
sis and liver metastasis[222].  Studies have shown that stable 
PRL3 expression increases cell motility and invasiveness and 
induces tumor formation and metastasis in mouse models[223]. 
In contrast, PRL3 siRNA knockdown blocks cell motility and 
metastasis, suggesting that PRL3 is a potential cancer treat-
ment target[224, 225].  PRL3 can upregulate PDGFR, Eph, and 
integrin receptor, as shown in a proteomic analysis of PRL3-
overexpressing HEK293 cells.  
Phosphoproteomic data support the intracellular activation 
of an extensive signaling network normally governed by extra-
cellular ligand-activated transmembrane growth factor, cyto-
kine, and integrin receptors in PRL3-overexpressing cells[226]. 
Similarly, PRL3 induces EGFR hyperactivation and its down-
stream signaling pathways in multiple human cancers, con-
tributing to cell growth, migration and tumorigenicity.  PRL3-
overexpressing cancer cells are highly sensitive to oncogenic 
EGFR signaling, as they are sensitive to EGFR inhibiting treat-
ment[227].  More recent studies of genetically modified mouse 
models demonstrate that PRL2 is required for several devel-
opmental processes (placenta, spermatogenesis, hematopoietic 
stem cell self-renewal) and reveal a novel mechanistic connec-
tion between PRL2 and PTEN[228–230].  Given the strong cancer 
susceptibility to subtle variations in PTEN levels, PRL2’s abil-
ity to repress PTEN expression qualifies it as an oncogene and 
a novel target for anti-cancer agents.  Taken together, PRLs are 
of great therapeutic importance as clinical predictive biomark-
ers for personalized medicine and novel drug targets for high 
metastatic potential cancers.
LMWPTP in cancer and diabetes
Low molecular weight protein tyrosine phosphatase (LMW-
PTP) has a single catalytic domain (Figure 2) with an approxi-
mate molecular weight of 18 kDa.  It is the sole class II PTP 
member, and its overall sequence and 3D structures are dif-
ferent from the aforementioned higher molecular weight 
PTPs, with the exception of the conserved PTP signature motif 
(P-loop).  LMWPTP is well conserved across many prokary-
otic and eukaryotic species, suggesting that it may play fun-
damental roles throughout evolution[231].  There are 4 human 
LMWPTP isoforms, and 2 are catalytically active, namely IF1 
and IF2 (or LMWPTP-A and LMWPTP-B)[232, 233].  These two 
isoforms have very high sequence and structure similarity, 
and the minor difference exists in a flexible loop flanking the 
active site, which is thought to determine their physiological 
substrate specificity[234].  Our knowledge of human LMWPTPs 
is primarily from the study of IF1.  
LMWPTP regulates many receptor tyrosine kinase and 
growth factor-induced signaling pathways, which control 
cell growth, differentiation and adhesion (Figure 6A).  For 
example, phosphorylated PDGF receptor is a well-known 
LMWPTP substrate dephosphorylated on Y857 in its β sub-
unit[235–237], which is a regulatory residue for PDGF receptor 
kinase activity.  LMWPTP also dephosphorylates Src kinase 
and STAT family transcription factors, and block their PDGF 
receptor-induced activation[238–240].  In addition, LMWPTP can 
dephosphorylate and inactivate FAK[241] and p190RhoGAP[242], 
which are involved in cell-extracellular matrix adhesion. 
More importantly, EphA2 is a preferred LMWPTP substrate 
in tumor cells[243–245].  EphA2 is a receptor tyrosine kinase over-
expressed in many human cancers, especially in aggressive 
and metastatic types[243].  In contrast to PDGF receptor, EphA2 
phosphorylation inhibits cell growth and migration, while its 
dephosphorylation induces oncogenic characteristics[246, 247]. 
LMWPTP overexpression in epithelial cells induces colony 
formation in soft agar and promotes neoplastic transforma-
tion[243].  LMWPTP-transfected NIH3T3 fibroblasts can induce 
larger fibrosarcomas in nude mice with higher proliferation 
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activity and greatly dephosphorylated EphA2 compared to 
mock-transfected controls.  The opposite was true in dominant 
negative/inactive LMWPTP-transfected cells[244].  Because 
LMWPTP is overexpressed in many tumor types, LWMPTP 
and EphA2 may form an oncogenic axis to promote tumor ini-
tiation, progression and metastasis.
LMWPTP is also a key negative regulator of insulin signal-
ing through tyrosine dephosphorylation of the insulin recep-
tor (IR) β subunits [248].  A study from Eli Lilly demonstrated 
that decreased LMWPTP expression by a specific antisense 
oligonucleotide (ASO) increases IR, PI3K, and AKT phosphor-
ylation, thus sensitizing insulin signaling[249].  ASO treatment 
resulted in decreased plasma insulin, glucose, triglyceride and 
cholesterol levels, with improved glucose and insulin toler-
ance in mice[249].  Interestingly, LMWPTP inhibition primarily 
affects liver and adipose tissues, in contrast to PTP1B, which 
regulates insulin signaling in liver and skeletal muscle.  These 
data suggest that PTP1B and LMWPTP have different tissue 
specificity in insulin signaling regulation[249].  Epidemiological 
studies have indicated that LMWPTP levels positively associ-
ate with serum glucose and triglyceride concentrations, and 
the highest LMWPTP levels have been recorded in diabetic 
and aged patients[250].  In addition, clinical studies have dem-
onstrated that genotypes with elevated LMWPTP IF1 isoforms 
have the highest diabetic retinopathy incidence, a common but 
severe diabetic complication[251].  These findings indicate that 
LMWPTP is also a novel type 2 diabetes drug target.  
CDC25 in cancer
The CDC25 phosphatases are dual-specificity phosphatases 
comprised of 3 members, CDC25A, CDC25B, and CDC25C, 
encoded by genes on 3 different chromosomes[252–255]. 
CDC25A, CDC25B, and CDC25C have 423 to 566 amino acids 
with a conserved C-terminal PTP catalytic domain and a non-
conserved N-terminal regulatory domain for various post-
translational modifications, including phosphorylation, ubiq-
uitination, proline isomerization, and 14-3-3 sequestration[256]. 
The CDC25 family plays critical roles in cell cycle control by 
dephosphorylating negative regulatory residues of cyclin-
dependent kinases (CDKs) (Figure 6B), which are important 
elements of cell cycle progression[257].  Specifically, CDC25A 
plays a significant role in the G1-S transition by activating the 
cyclin A and cyclin E-CDK2 complexes[258–260]; CDC25B par-
tially activates the centrosomal cyclin B-CDK1 complex during 
the G2 to mitosis transition, and nuclear CDC25C further acti-
vates the complex during mitosis[261–263].  
Dysregulated cell cycle control is a hallmark of cancer cells 
to gain a growth advantage.  Thus, the CDC25 family has 
gained much attention as potential cancer drug targets[256, 264]. 
Studies have shown that CDC25 causes cell cycle deregulation 
and consequent cell genome instability, which contributes to 
cancer initiation and progression.  For instance, CDC25A and 
CDC25B can transform normal mouse embryonic fibroblasts 
into oncogenic foci in soft agar and tumors in nude mice with 
oncogenic Ras or loss of RB1[265].  CDC25B expression enhances 
mammary epithelial cell proliferation and induces precocious 
alveolar hyperplasia[266], and further increases tumor onset sus-
ceptibility upon carcinogen exposure (9,10-dimethyl-1, 2-benz-
anthracene, DMBA)[267].  CDC25A, CDC25B, and CDC25C 
have been found to be overexpressed in a number of human 
cancers, including breast, colon, gastric, lung, colorectal, pan-
creatic, neuroblastoma, head and neck, and non Hodgkin’s 
lymphoma[264], and their overexpression occurs at all stages 
of tumorigenesis, suggesting that they may play critical roles 
throughout tumor development.  Various small molecule 
CDC25 inhibitors have been developed and possess anti-
cancer properties.  For example, the IPSEN research laboratory 
developed BN82685 to inhibit CDC25A, B, C with IC50 values 
of 250, 250, and 170 nmol/L, respectively[268].  This compound 
blocks proliferation across a large panel of human cells, as 
well as tumor growth in xenograft mice with the pancreas car-
cinoma cell line Mia PaCa-2[268].  Therefore, the CDC25 family 
of phosphatases represent novel and attractive cancer targets.
Strategies to modulate PTP activity
There are several ways to modulate PTP activity, and the 
most popular strategy is to design active site directed and 
non-hydrolyzable pTyr mimetic-based small molecules.  This 
technique has successfully produced potent inhibitors against 
several PTPs[7, 25].  However, the major challenges of this 
strategy are specificity due to conserved PTP structure, and 
cell permeability due to the positively charged PTP active sites. 
The cell permeability and inhibitor specificity are important 
Figure 6.  The physiological/pathological signal pathways involving 
LMWPTP (A) and CDC25 (B).  Arrow represents positive regulation.  T-bar 
represents dephosphorylation if it points to a phosphate group or specific 
pY, otherwise it represents negative regulation.  See the text for regulation 
details.
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considerations in PTP-based drug discovery because PTP 
domains are cytosolic and many PTPs may function as tumor 
suppressors and should not be inadvertently targeted.  The 
recent discovery of cell permeable pTyr mimetic salicylic 
acid-based inhibitors have achieved appreciable success in 
addressing these challenges[269].  
Targeting allosteric PTP1B sites is a good strategy in the 
development of high specificity and cell permeability inhibi-
tors[270].  Allosteric inhibitors are not required to have multiple 
negative charges and therefore may possess more favorable 
pharmacological properties.  However, it still seems difficult 
to improve their potency, as allosteric sites are not as well-
defined as the active site.  
Another strategy is to develop mechanism-based inhibitors, 
which inactivate the PTP catalytic cysteine residue through 
oxidation or other modifications.  This strategy has been 
employed in quinone-based CDC25 inhibitors[11].  However, 
quinone compounds may induce reactive oxygen species, 
which may inactivate various redox-sensitive enzymes and 
cause in vivo toxicity[271, 272].  Although they seemingly possess 
great activities against PTPs in vitro, they are not appealing for 
drug development.  Irreversible and selective kinase inhibi-
tor development has generated renewed interest in covalent 
enzyme inhibitors[273, 274].  This can be achieved by building a 
Michael acceptor into a known competitive and specific inhibi-
tor, which then forms a covalent bond with an adjacent cys-
teine residue.  Thus, it will be interesting to employ a similar 
approach to develop irreversible and specific PTP inhibitors. 
Unlike quinone-based PTP inhibitors, these irreversible inhibi-
tors would not target all redox-sensitive enzymes in cells.  
In addition, ASOs against PTP1B and LMWPTP have been 
reported[249, 275, 276].  Because they are ~20-mer oligonucleotides 
that target PTP mRNA, they are highly specific.  PTP1B and 
LMWPTP ASOs have been reported to increase insulin sensi-
tivity, reduce body glucose level, and control weight gain in 
animal studies and clinical trials, indicating their therapeutic 
potential.  siRNAs may be an alternative approach in targeting 
PTPs through similar mechanisms.  Nevertheless, challenges 
include low target delivery efficiency and safety of long-term 
consumption.
Concluding remarks
Protein-tyrosine phosphorylation dysregulation is a major 
cause of various human diseases, and great success has been 
achieved in PTK target drug discovery[3].  PTPs represent 
promising next generation drug targets for decades to come. 
For instance, PTP1B and LMWPTP are well-known negative 
regulators of the insulin signaling pathway and are excellent 
drug targets for type 2 diabetes and insulin resistance.  SHP2, 
PRLs, LMWPTP, CDC25, CD45, FAP-1, and MKP-1 play posi-
tive roles in tumorigenesis by distinct mechanisms, and they 
can be targeted to combat a number of human cancers or to 
sensitize cancer chemotherapy or radiation therapy.  LYP 
and CD45 are exciting drug targets for autoimmune diseases, 
such as type 1 diabetes, rheumatoid arthritis, and systemic 
lupus erythematosus.  As a brain-restricted PTP, STEP is an 
emerging target for neurological disease and disorder treat-
ment, such as Alzheimer’s disease, Huntington’s disease, 
schizophrenia, and alcohol abuse.  In addition, MKP-1 may be 
relevant in depression and may be a novel target for this com-
mon and debilitating neurological illnesses.  
Although there is growing recognition of PTPs as promis-
ing therapeutic targets, there are no commercialized PTP 
inhibitors despite extensive pharmaceutical industry efforts. 
The reasons for this lack of success in PTP-based drug discov-
ery are both historical and technological.  Historically, PTP 
research and development has run approximately 10 years 
behind PTK research because PTKs were discovered earlier 
and because PTPs have been erroneously viewed as exclusive 
negative regulators of hyperactive pathways in disease.  Prior 
to the Human Genome Project, it was commonly believed that 
PTPs constituted a small group of ‘housekeeping’ enzymes 
with functions too broad and conserved to be selectively ther-
apeutically inhibited.  It is now known that there are actually 
more PTPs (107) than PTKs (90), and accordingly, many PTPs 
have unique and non-redundant functions in health and dis-
ease, making them attractive drug targets.
Unfortunately, PTPs present several key challenges to 
traditional drug development.  The PTP active site is highly 
conserved, so it is not trivial to produce compounds that can 
selectively inhibit single PTPs.  This is an issue common to 
most target families that act upon common substrate motifs 
(such as pTyr for PTPs or ATP for kinases) and has been over-
come in the kinase field by high throughput screening and 
structure-based drug design.  A more serious issue in PTP-
based drug discovery is that the PTP active site is highly posi-
tively charged and contains a conserved catalytic cysteine resi-
due.  Thus, high-throughput screening of large compound col-
lections usually leads to initial hits that are strongly negatively 
charged or contain oxidizing groups that irreversibly react 
with the catalytic cysteine.  Heavily charged molecules do not 
readily cross cell membranes and cannot be made into drugs 
in their native form, and chemically-reactive compounds (eg, 
quinones) have poor safety and selectivity profiles, making 
them unappealing drug candidates.  Despite these challenges, 
a new, focused, pragmatic approach to PTP inhibitor drug 
discovery and development is required.  Recent studies using 
fragment-based and structure-guided approaches to target 
the PTP active site and adjacent less-conserved pockets dem-
onstrate that it is feasible to obtain PTP inhibitors with high 
affinity, selectivity, and excellent in vivo efficacy in animal 
models of oncology, diabetes/obesity, autoimmunity, and 
tuberculosis[277].  Further work will advance the lead genera-
tion paradigm and create a ‘PTP-based drug discovery plat-
form’ that will ultimately broadly impact drug development 
of tomorrow.
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